Journal article icon

Journal article

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Abstract:

Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regimens (CCR; n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of patients) cytogeneti...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1038/s41375-018-0257-z

Authors


Döhner, H More by this author
Seymour, JF More by this author
Minden, MD More by this author
Expand authors...
Publisher:
Springer Nature Publisher's website
Journal:
Leukemia Journal website
Volume:
32
Pages:
2546–2557
Publication date:
2018-10-01
Acceptance date:
2018-08-06
DOI:
EISSN:
1476-5551
ISSN:
0887-6924
Pubs id:
pubs:923843
URN:
uri:17a44c7a-d4d0-4d37-a8fb-7b07c42520bf
UUID:
uuid:17a44c7a-d4d0-4d37-a8fb-7b07c42520bf
Local pid:
pubs:923843
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP